2,379 results on '"Kumada, Hiromitsu"'
Search Results
202. Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
203. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001
204. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment
205. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C
206. Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis
207. Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection
208. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy
209. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
210. Effect of Acute Self-Limited Hepatitis C Virus (HCV) Superinfection on Hepatitis B Virus (HBV)-Related Cirrhosis. Virological Features of HBV–HCV Dual Infection
211. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine
212. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment
213. Cover Image, Volume 92, Number 12, December 2020
214. Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years
215. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
216. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis
217. CASE REPORT: Interferon-α for Reinfection with Hepatitis C Virus in Two Patients with Chronic Hepatitis C Who Had Responded to Previous Therapies
218. Clinical features of hepatitis B virus genotype A in Japanese patients
219. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy
220. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load
221. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan
222. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma
223. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan
224. Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease
225. Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma
226. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients
227. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
228. Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B
229. Quantification of collagen and elastic fibers using whole-slide images of liver biopsy specimens
230. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
231. Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis
232. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
233. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
234. Long-Term Clinical Remission Induced by Corticosteroid Withdrawal Therapy (CSWT) in Patients with Chronic Hepatitis B Infection: A Prospective Randomized Controlled Trial—CSWT with and Without Follow-Up Interferon-α Therapy
235. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C
236. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis
237. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load
238. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy
239. A functional SNP of DEPDC5 modulates gene transcription level through the allele-specific binding of FOXA1/2: 1020
240. Comparison of Pre-Existing and Emerging Resistance-Associated Variants in US, EU and Japanese HCV Genotype 1b Prior Interferon Alfa (IFN-α) Non Responders and IFN-α Ineligible Patients Treated with Daclatasvir and Asunaprevir: 763
241. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with chronic hepatitis B: 357
242. Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis
243. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen
244. Rapid Decrease of Plasma HCV RNA in Early Phase of Twice Daily Administration of 3 MU Doses Interferon-β in Patients with Genotype 1b Hepatitis C Infection
245. Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant
246. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B.
247. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
248. Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage.
249. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts
250. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.